Domenico Magazzù

5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial

Luca Gianni, Tadeusz Pieńkowski, Young‐Hyuck Im et al. · The Lancet Oncology · 2016 · 846 citations

5-Year Analysis, Breast Oncology, Medicine +7

Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohort

Luca Gianni, W. Eiermann, Aňa Lluch et al. · The Lancet Oncology · 2014 · 487 citations

Breast Oncology, Oncology, Superiority Trial +7

Comparing Neoadjuvant Nab-paclitaxel vs Paclitaxel Both Followed by Anthracycline Regimens in Women With <i>ERBB2/HER2</i> -Negative Breast Cancer—The Evaluating Treatment With Neoadjuvant Abraxane (ETNA) Trial

Luca Gianni, Mauro Mansutti, Antonio Antón et al. · JAMA Oncology · 2018 · 153 citations · Full text

Occult hepatitis B virus infection is associated with the development of hepatocellular carcinoma in chronic hepatitis C patients

Giovanni Squadrito, Teresa Pollicino, Irene Cacciola et al. · Cancer · 2006 · 134 citations · Full text

Immune modulation of pathologic complete response after neoadjuvant HER2-directed therapies in the NeoSphere trial

Giampaolo Bianchini, Lajos Pusztai, Tadeusz Pieńkowski et al. · Annals of Oncology · 2015 · 133 citations

Neosphere Trial, Cancer Immunosurveillance, Pathologic Complete Response +12